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Abstract
Background: The co-circulation of 4 DENV serotypes in geographically expanding area, has resulted in increasing
occurrence of DENV co-infections. However, studies assessing the clinical impact of DENV co-infections have been
scarce and have involved small number of patients. This study explores the impact of DENV co-infection on clinical
manifestations and laboratory parameters.
Methods: This retrospective study involved consecutive hospitalized patients with non-structural protein 1 (NS1)
antigen positivity during an outbreak (Jan to April 2014). Multiplex RT-PCR was performed directly on NS1 positive
serum samples to detect and determine the DENV serotypes. All PCR-positive serum samples were inoculated onto C6/
36 cells. Multiplex PCR was repeated on the supernatant of the first blind passage of the serum-infected cells. Random
samples of supernatant from the first passage of C6/36 infected cells were subjected to whole genome sequencing.
Clinical and laboratory variables were compared between patients with and without DENV co-infections.
Results: Of the 290 NS1 positive serum samples, 280 were PCR positive for DENV. Medical notes of 262 patients were
available for analysis. All 4 DENV serotypes were identified. Of the 262 patients, forty patients (15.3 %) had DENV co-
infections: DENV-1/DENV-2(85 %), DENV-1/DENV-3 (12.5 %) and DENV-2/DENV-3 (2.5 %). Another 222 patients (84.7 %)
were infected with single DENV serotype (mono-infection), with DENV- 1 (76.6 %) and DENV- 2 (19.8 %) predominating.
Secondary dengue infections occurred in 31.3 % patients. Whole genome sequences of random samples representing
DENV-1 and DENV-2 showed heterogeneity amongst the DENVs.
Multivariate analysis revealed that pleural effusion and the presence of warning signs were significantly higher in the
co-infected group, both in the overall and subgroup analysis. Diarrhoea was negatively associated with co-infection.
Additionally, DENV-2 co-infected patients had higher frequency of patients with severe thrombocytopenia (platelet
count < 50,000/mm3), whereas DENV-2 mono-infections presented more commonly with myalgia. Elevated creatinine
levels were more frequent amongst the co-infected patients in univariate analysis. Haemoconcentration and
haemorrhagic manifestations were not higher amongst the co-infected patients. Serotypes associated with severe
dengue were: DENV-1 (n = 9), DENV-2 (n = 1), DENV-3 (n = 1) in mono-infected patients and DENV-1/DENV-2 (n = 5)
and DENV-1/DENV-3 (n = 1) amongst the co-infected patients.
Conclusion: DENV co-infections are not uncommon in a hyperendemic region and co-infected patients are skewed
towards more severe clinical manifestations compared to mono-infected patients.
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Background
Dengue virus (DENV) infection is a global health threat,
with approximately half of the world’s population at risk
of being infected and 0.5 million people requiring
hospitalization each year [1]. It is amongst the most im-
portant vector-borne viral disease of humans. A recent
estimate suggests that there are 96 million apparent
DENV infections globally per year with Asian countries
bearing 70 % of this burden [2], making this region an
epicentre of dengue activity. DENV infections can lead
to a wide range of clinical manifestations, ranging from
mild fever to potentially fatal dengue shock syndrome.
Previously classified as dengue fever (DF), dengue haem-
orrhagic fever (DHF) and dengue shock syndrome (DSS)
[3], World Health Organization (WHO) dengue classifi-
cation 2009 classifies dengue as dengue with or without
warning signs and severe dengue [4].
DENV, a positive-stranded RNA virus of the Flaviviri-
dae family has 4 distinct serotypes (DENV-1, DENV-2,
DENV-3 and DENV-4). DENV is transmitted to humans
by the Aedes mosquito, principally the Aedes aegypti
mosquito [5]. Dengue has now become hyper-endemic
in many countries including Malaysia with all four
DENV serotypes co-circulating, with fluctuations of the
dominant serotypes over time and location [6]. To date,
studies describing the wide arrays of clinical characteris-
tics associated with different DENV serotypes have been
widely described. Some studies have suggested that
DENV-2 leads to more severe disease, whereas DENV-1
is responsible for milder illness [7]. The co-circulation of
multiple DENV serotypes in the same region, invariably
facilitates the occurrence of co-infections with rates
ranging from 5 % to 30 % [8–15] to as high as 40 % to
50 % [16, 17]. This phenomenon has heightened the
importance of understanding the role of co-infections
in the clinical outcome of disease. However, although
DENV co-circulation is reasonably common in trop-
ical countries, very little emphasis has been placed so
far on co-infections. Moreover, only a handful of stud-
ies have actually explored the clinical implications of
co-infections [8, 10, 12, 14, 17]. Vast majority of these
studies were descriptive in nature and the numbers of
co-infections were rather small to reach valid statis-
tical conclusions.
Thus, there still remains an unresolved question as to
whether the clinical manifestations of dengue vary
between co-infected and mono-infected patients. In an-
ticipation of an increasing number of co-infections,
exploring the various characteristics and disease severity
associated with co-infections, will undoubtedly enhance
our understanding of the dynamics and impact of these
infections. To the best of our knowledge, this study has
the largest number of DENV co-infected patients, allow-
ing more reliable interpretation of findings.
This study aims to determine the clinical and labora-
tory characteristics amongst patients hospitalized with
DENV infections, specifically exploring the effects of
DENV co-infections on these patients.
Methods
Patients and setting
This research was conducted at Hospital Sultanah Ami-
nah Johor Bahru (HSAJB), a 989-bedded hospital that
serves as the main tertiary referral centre of Southern
Malaysia, with its patient population reflecting the larger
community in Malaysia. The period of study was from
January to April 2014, coinciding with one of the peaks
of DENV outbreaks. During the study period, all hospi-
talized patients with a positive non-structural protein 1
(NS1) antigen were identified from the microbiology
laboratory database, HSAJB. The initial NS1 testing was
done at the microbiology laboratory of HSAJB, using a
commercially available rapid dengue diagnostic kit; SD
BIOLINE Dengue Duo combo device (Standard Diag-
nostic Inc., Korea). Secondary DENV infections were
detected using Panbio Dengue IgG Capture ELISA,
which has incorporated a cut-off value of > 22 Panbio
Units, equivalent to HAI level of 1:2560, indicative of
secondary infections [18].
Clinical data was retrospectively collected by reviewing
the medical case notes, microbiology, haematology and
biochemical laboratory results. The clinical data re-
trieved on admission included demography, vital signs,
underlying comorbidities, signs and symptoms, haem-
atological, liver and renal function parameters. Warning
signs and severe dengue manifestations were recorded
throughout the hospital stay. In addition, nadir platelet
counts and results of dengue serology were also noted.
Approval was obtained from the Medical Research
Ethics Committee, Ministry of Health Malaysia (NMRR-
14-617-21061). Informed consent was not obtained from
the patients, as this was a retrospective study and data
was analyzed anonymously.
In total 290 patients (non-duplicate) with NS1 antigen
positive were identified. Their serum samples were
stored at -80 °C for further testing. These tests were
conducted at an infectious diseases research laboratory
at Monash University Malaysia.
Patients’ serum samples and extraction of viral DNA
Viral RNA was extracted from 200 μl of the original
serum using QIAamp viral RNA Mini Kit (Qiagen,
Germany) according to the manufacturer’s instructions.
Extracted RNA was stored either at -80 °C or used for
RT-PCR immediately. Complementary DNA (cDNA)
from viral RNA was synthesized by reverse transcription
using AccessQuick RT-PCR System kit (Promega, USA).
The RT mixture consisted of 10 μl (20–50 ng) of
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extracted RNA, 1 unit of reverse transcriptase enzyme,
12.5 μl of AccessQuick mastermix (2x), 1 μl of random
primer and 20 U of RNase inhibitor (RNaseOUT, Invi-
trogen) in a final volume of 20 μl. The RT mixture was
incubated at 65 °C for 5 min (min) followed by 37 °C for
1 h (h) and 72 °C for 5 min. The prepared cDNA was
used for multiplex PCR.
Multiplex PCR
DENV serotypes were determined using multiplex PCR
[19], which amplified specific target regions using a for-
ward conserved 5’UTR primer and four reverse primers
targeting specific regions of the M and C genes of re-
spective DENV-1, -2, -3 and -4 serotypes. To ensure the
specificity of the primers to DENV and the absence of
cross-reactivity with related flaviviruses, the primers
were blasted through the National Centre for Biotech-
nology Information database [19]. Amplifications were
performed as described and the expected size of each of
the amplicons was as follows: DENV-1:342 bps, DENV-
2: 251 bps, DENV-3: 538 bps and DENV-4: 754 bps. To
perform PCR, a primer mix was prepared by mixing 400
nM of forward conserved primer and 200 nM of each
reversed primer with appropriate volume of DEPC-
treated distilled water. The premix was added to PCR
buffer containing 1.5 mM MgCl2, 0.2 mM of each of the
dNTPs, 5U of Taq polymerase and 2 μl of viral cDNA.
The thermal cycling profile of this assay consisted of 35
cycles of PCR at 95 °C denaturation for 30 s (s), 60 °C of
annealing for 30 s and 72 °C extension for 1 min [19].
PCR contamination was avoided by spatially separating
the RNA extraction, cDNA preparation and amplifica-
tion steps. In order to detect possible contamination, a
no template negative control was incorporated in all the
PCR reactions.
All samples were also subjected to RT-PCR for
Chikungunya virus based on its non-structural protein 1
(nsP1) and glycoprotein E1 (E1) genes [20]. Chikungunya
virus infections are relatively common in Malaysia and
can mimic DENV infections in clinical presentations. PCR
was performed in a Mastercycler gradient machine
(Eppendorf, Hamburg, Germany).
Gel elution and sequencing of amplicons
The detection and identification of DENV direct from
serum samples by RT-PCR was accomplished based on
the product size of the amplified-serotype specific ampli-
cons by electrophoreses in a 1.5-2 % agarose gel stained
with ethidium bromide. PCR products were cut from
the gel, extracted using the QIAquick Gel Extraction kit
(Qiagen, Germany) and were directly sequenced in both
forward and reverse directions using the specific primers
by a commercial sequencing services (First base,
Singapore). Random amplicons of DENVs (DENV-1: 30,
DENV-2: 30, DENV-3: 13 and DENV-4:1) were selected
from the PCR reactions that showed both single and
dual DENV infections. The identities of the sequences
were confirmed by Basic Local Alignment Search Tool
(BLAST). The sequences obtained in the present study
and other sequences retrieved from the GenBank were
aligned in ClustalW (2.1).
Virus propagation in C6/36 cells and total viral RNA
extraction for next generation sequencing (NGS)
Confluent Aedes albopictus C6/36 monolayer cells were
grown and maintained in minimum essential medium
(MEM) supplemented with 2 % fetal bovine serum
(FBS), HEPES buffer and 1 % penicillin/streptomycin
(100 U/mL penicillin, 100 μg/mL streptomycin; Gibco®;
USA). Virus isolation was performed by inoculating 50
μl of original serum onto C6/36 monolayer cells in
Leighton tubes which were incubated at 30 °C for 7 to
10 days for growth of viruses. Viral RNA was extracted
from 200 μl of the first blind passage of the serum-
infected C6/36 culture supernatant and cDNA was syn-
thesized using the method described above. The cDNA
was used for multiplex PCR [19] and NGS. The ampli-
cons derived from the multiplex PCR of supernatant of
the first passage of the C6/36 infected cells were
compared with those derived directly from serum. To
confirm the DENV serotypes and to determine the het-
erogeneity of these viruses, random samples of five
DENV-1 and six DENV-2 from mono-infected samples
were subjected to NGS.
Whole genome sequencing of DENV
Synthesized cDNA was converted into double stranded
DNA using NEBNext® mRNA Second Strand Synthesis
Module (New England Biolabs, Ipwich, MA) according
to the manufacturer’s instructions. The reaction was
purified using Ampure bead XP (0.8× vol. ratio), normal-
ized to 0.2 ng/uL based on Qubit quantification (Invitro-
gen, Carlsbad, CA) and tagmented with Nextera XT
(Illumina, San Diego, CA) according to the manufac-
turer’s instructions for small insert size library. The
constructed libraries were quantified, normalized and se-
quenced on the MiSeq sequencer located at the Monash
University Malaysia Genomics Facility (run configuration
of 2 × 150 bps paired-end read). Reference mapping to
the complete genome of DENV was performed using
MITObim version 1.8 (default setting) [21]. The assem-
bled genomes of 6 DENV-2 and 5 DENV-1 (DENV-2:
TM26, TM78, TM181, TM198, TM213, TM296; DENV-
1: TM24, TM50, TM99, TM100, TM242) along with
additional closely related genomes of DENV isolated
from the South East Asia and Oceania regions were used
to infer evolutionary relationship. Nucleotide alignment
based whole genome sequence was performed using
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MAFFT v7.127b (default alignment setting) and a max-
imum likelihood phylogenetic tree was constructed using
FastTree version 2.1.8 with the Jukes-Cantor + CAT
model [22, 23]. Tree visualization and editing was
performed using FigTree v1.4.1 (http://tree.bio.ed.ac.uk/
software/figtree/). Further classification of genotypes in
each serotype was determined using the Genotype Deter-
mination and Recombination Detection tool on Virus
Pathogen Resource (http://www.viprbrc.org/brc/genoty-
peRecombination.spg?method=ShowCleanInputPage&de
corator=flavi_dengue).
Definition
Warning signs (WS) assessed included abdominal pain
or tenderness, persistent vomiting (≥2 consecutive
days), clinical fluid accumulation, mucosal bleeding,
hepatomegaly (>2 cm) and haematocrit rise concur-
rent with a rapid decrease in platelet counts [4]. We
chose to exclude lethargy as a WS due to ambiguity in
patients’ perception of lethargy and lack of objective
distinction from tiredness [24]. The definition for se-
vere dengue was obtained from the WHO 2009
criteria [4] with minor modifications and comprised at
least one of the three criteria:
a) Severe plasma leakage leading to shock (narrowing
of pulse pressure to ≤ 20 mmHg, systolic blood
pressure < 90 mm Hg or the presence of signs of
poor capillary perfusion such as cold extremities,
poor capillary refill or tachycardia) [3, 4] or fluid
accumulation with respiratory distress (respiratory
rate ≥30/min with oxygen saturation ≤ 92 % on
room air, or requiring mechanical ventilation) [25].
b) Severe bleeding was defined as bleeding with
hemodynamic instability that requires fluid
replacement for shock and/or whole blood or
packed cell transfusion or any life threatening
bleed, e.g. haematemesis, melaena or intracranial
bleed [25].
c) Severe organ impairment comprised severe liver
impairment (aspartate aminotransferase or alanine
aminotransferase ≥1000 IU/L), encephalopathy,
myocarditis [4] or acute renal impairment (Stage 2
Acute Kidney Injury) [26, 27].
Based on population background study conducted in
Malaysia, the haematocrit parameters used to evaluate
haemoconcentration were >40 % in female adults, > 46 %
in male ≤ 60 years, > 42 % in male > 60 years and > 38 %
in children [28]. Leukopenia was defined as leukocyte
count < 4,000/mm3 and thrombocytopenia as platelet
count <150,000/mm3. Severe thrombocytopenia was re-
ferred to as platelet count < 50,000/mm3, a value shown
to be associated with additional severe manifestations [7].
Paediatric patients were defined as patients aged less than
18 years. Secondary DENV infections categorization was
based on the results of Panbio dengue IgG capture ELISA
[18]. Pleural effusion or ascites was diagnosed based on
conventional x-rays or ultrasound of the thorax and ab-
dominal region. Diarrhoea was defined as the passage of
three or more loose stools per day [28]. The simultaneous
detection of more than one DENV serotypes was classified
as co-infection, in contrast to mono-infection where only
one DENV serotype was identified.
Data was analyzed using the Statistical Package for
Social Sciences (SPSS version 20.0); comparing patients
with and without DENV co-infections. To further pin-
point the variances in clinical and laboratory findings
attributable to a particular serotype and its co-infection,
subgroup analysis (DENV-1 and DENV-2 with its re-
spective co-infection) was performed. Similar analysis
was not conducted for DENV-3 and DENV-4 as the
numbers were too small for valid statistical comparison.
Categorical variables were expressed as numbers and
percentages and comparison amongst variables was de-
termined by the Fisher’s exact test or Chi-squared test.
Continuous variables were expressed as median ± inter-
quartile range (IQR) and comparison was made using
the non-parametric Mann–Whitney test. The odds ratio
(OR) and its 95 % confidence intervals (CI) were calcu-
lated. The p-value < 0.05 (two-tailed) was taken as the
level of significance. We then performed a multivariate
logistic regression analysis by including clinical manifes-
tations and laboratory parameters which were significant
in univariate analysis (P < 0.05), to evaluate the factors
independently associated with co-infections. To obtain
more reliable results, variables with more than 5 % of
missing data were excluded from the final model.
Results
Serotype distribution and phylogenetic analysis of DENV
In total 290 non-duplicate NS1 antigen positive serum
samples were identified during the study period. DENV
serotypes were determined by multiplex RT-PCR directly
from original serum samples and from the supernatant
of the first passage of C6/36 serum infected cells. The
results showed the amplicons generated from both the
multiplex RT-PCR were consistent with each other. Ten
of the 290 samples were PCR negative for DENV. Based
on the primer designs [19] these 10 samples were also
negative for other flaviviruses. All the 290 samples were
negative for Chikungunya virus. Of the remaining 280
samples, single DENV serotypes indicating mono-
infection were detected in 238 (85 %) samples, while
dual serotypes indicating co-infection were found in 42
(15 %) samples.
Medical notes for 262 of 280 patients were available
for analysis (not traceable; n = 8; incomplete; n = 6;
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transferred out; n = 4). Details on DENV serotypes,
demography and comorbidities are presented in Table 1.
Two hundred twenty-two patients (84.7 %) were in-
fected with a single DENV serotype and 40 patients
(15.3 %) had DENV co-infections. Amongst the mono-
infections, DENV- 1 (76.6 %) was by far the most
common serotype identified followed by DENV- 2 (19.8
%). Seven DENV-3 were identified, and only one
DENV- 4 was identified. Amongst the co-infected pa-
tients, the predominant combinations were DENV-1/
DENV-2 (85 %), followed by DENV-1/DENV-3 (12.5 %)
and DENV-2/DENV-3 (2.5 %). Secondary dengue infec-
tions occurred in 31.3 % of the cases.
Sequencing of representative amplicons from the
mono and co-infected samples confirmed the serotype
of each of the DENV. The consensus sequence of
DENV-1 amplicon of size 342 bps, DENV-2 of 251 bps
and DENV-3 of 538 bps were 95 % to 100 % similar
for all the randomly selected 30 amplicons of DENV-
1, 30 amplicons of DENV-2 and 13 amplicons of
DENV-3 respectively.
Phylogenetic analysis based on whole genome se-
quence indicates some degrees of genomic heterogeneity
among the DENV strains as evidenced by the terminal
branch length in the maximum likelihood tree. The
constructed phylogenomic tree exhibited the expected
clustering of viral sequences based on their serotypes
and genotypes (Fig. 1). All six DENV-2 isolates reported
in this study fall within the same Cosmopolitan genotype
and also share a common ancestry with strong bootstrap
support (100 %) to DENV-2 virus isolated from regions
located south of Peninsular Malaysia e.g. Singapore and
Indonesia. This pattern of monophyletic clustering is
also observed with the newly isolated DENV-1 virus but
with a lower bootstrap support (60 %) in the DENV-1
clade with the exception of strain TM242, which is basal
to the rest of the DENV-1 strains included in the phylo-
genomic analysis. Additionally, only TM242 has a differ-
ent genotype-V while the other four reported DENV-1
strains are genotype-I. In both DENV-1 and DENV-2
lineages, the viral isolates from northern Southeast Asia
countries such as Thailand, Cambodia and Vietnam are
sister taxa to all or most viral isolates from Malaysia,
Singapore and Indonesia, suggesting correlation with
biogeography.
Demography and comorbidities
Baseline demographic and comorbidity data is shown in
Table 1. The patients’ age ranged from 3 to 75 years
(median 27.75 years). There were 38 (14.5 %) paediatric
patients. Majority of the patients were Malays (59.9 %).
Excluding 14 pregnancies, one-fifth of patients had at
least one pre-existing comorbidity; diabetes mellitus be-
ing the commonest.
The impact of DENV co-infection on clinical and labora-
tory parameters on admission
Overall, the most commonly reported symptoms on ad-
mission were fever (99.2 %), vomiting (62.6 %), myalgia
(59.5 %) and arthralgia (56.9 %). Particularly noteworthy
Table 1 Serotype distribution, demography and comorbidities
of DENV infected patients
Characteristics N (%)
DENV serotypes
Mono-infection 222 (84.7)
DENV-1 170 (76.6)
DENV-2 44 (19.8)
DENV-3 7 (3.2)
DENV-4 1 (0.5)
Co-infection 40 (15.3)
DENV-1/DENV-2 34 (85)
DENV-1/DENV-3 5 (12.5)
DENV-2/DENV-3 1 (2.5)
Race
Malay 157 (59.9)
Chinese 34 (13)
Indian 29 (11.1)
Foreign workers 37 (14.1)
Others 5 (1.9)
Male 146 (55.7)
Age groups
<18 38 (14.5)
18-29 104 (39.7)
30-39 64 (24.4)
40-49 27 (10.3)
50-59 17 (6.5)
>60 12 (4.6)
Pregnancy 14 (5.3)
Comorbiditiesa 52 (19.8)
Diabetes mellitus 21 (8)
Hypertension 15 (5.7)
Asthma 14 (5.3)
Cardiovascular disease 6 (2.3)
Blood disorderb 4 (1.5)
Malignancyc 4 (1.5)
Psychiatric disorders 4 (1.5)
Othersd 5 (1.9)
aA patient may have more than one comorbidities
bIncludes G6PD deficiency (n = 2), beta-thalassaemia (n = 1), von Willebrand
disease (n = 1)
cIncludes cancer of breast (n = 1), ear (n = 1), pancreas (n = 1), ovary (n = 1)
dOne patient each had- chronic obstructive airway disease, military tuberculosis,
splenectomy, end stage renal failure, systemic lupus erythematosus
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was the presence of diarrhoea in almost half the patients
(45.8 %). The median (IQR) duration of symptoms
before hospitalization was 4 (1 to 10) days. Raised
haematocrit, severe thrombocytopenia (platelets <
50,000/mm3) and leukopenia on admission were
detected in 54.2 %, 15 % and 66.8 % of patients respect-
ively. A substantial proportion of patients had elevated
liver enzymes; 78.2 % and 61 % for AST and ALT re-
spectively, with levels more than 10 times the normal
upper limit noted in 5.5 % of patients. Elevated
Fig. 1 Maximum likelihood phylogeny of DENV-1 and DENV-2 strains from South East Asia and Oceania. The tree was rooted against DENV-1 (Maroon
branches). Filled black circles in front of taxon names indicate strains that were sequenced and reported in this study. Taxon names are abbreviated by
their Genbank accession number followed by country and strain name. Values at nodes indicate bootstrap support. Genotype classification within
serotype is indicated by genotype name beside each group, within a coloured-region. Genotype I, IV and V in DENV1; genotype Cosmopolitan, Asian
American (A/A), Asian-II and Asian-I in DENV-2. For clarity, the branch leading to DENV-1 has been shortened and indicated with the real length. (Scale
bar: average number of substitutions per site)
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creatinine levels were observed in 13.5 % of patients.
However, except for two patients, one with pre-existing
renal failure, the creatinine levels were within 50 % of
the upper limits of normal.
Univariate analysis of the comparison of clinical and
laboratory findings upon admission between patients
with and without DENV co-infection are shown in
Tables 2 and 3. Overall, the following clinical symptoms
and laboratory results on admission were significantly
different (p < 0.05) among patients who developed
DENV co-infections compared with those with mono-
infections: diarrhoea (OR: 0.39; 95 % C1:0.19-0.83), fever
(OR: 1.18; 95 % C1:1.12-1.25) and elevated creatinine
(OR: 2.87; 95 % C1:1.23-6.70); with the latter two
findings higher in the co-infected group. Similarly, on
sub-group analysis, the DENV-1 co-infected patients re-
ported diarrhoea less frequently (OR: 0.37; 95 % C1:
0.17-0.81) and were more frequently febrile (OR: 1.23;
95 % C1: 1.15-1.31) and exhibited elevated creatinine
more often (OR: 2.80; 95 % C1:1.17-6.72). DENV-2 co-
infected patients had a lower number of patients
presenting with myalgia (OR: 0.35; 95 % C1: 0.13-
0.92), arthralgia (OR: 0.34; 95 % C1: 0.13-0.93) and
diarrhoea (OR: 0.32; 95 % C1: 0.12-0.83) and a higher
frequency of fever (OR: 1.81; 95 % C1: 1.49-2.22)
compared to mono-infected patients. In addition, se-
vere thrombocytopenia was significantly higher in the
DENV-2 co-infected group (OR: 10.75; 95 % C1: 1.25-
92.16). DENV-2 co-infected patients also had signifi-
cantly lower nadir platelet counts compared to the
mono-infected group (p = 0.017).
Multivariate analysis showed that the following clinical
findings and laboratory results were independently asso-
ciated with co-infections. Overall, diarrhoea was nega-
tively associated with co-infections (OR: 0.326; 95 % CI:
0.149-0.711). Likewise, diarrhoea was less common in
DENV-1 (OR: 0.339; 95 % CI: 0.151-0.764) and DENV-2
co-infections (OR: 0.24; 95 % CI: 0.077-0.753), compared
to the mono-infected group. In addition, DENV-2 co-
infected group had a higher frequency of patients with
severe thrombocytopenia on admission (OR: 12.561; 95
% CI: 1.297-121.647), whereas the DENV-2 mono-
infected group had a higher number of patients mani-
festing with myalgia (OR: 0.306; 95 % CI: 0.102-0.919).
Although elevated creatinine levels were significantly
higher in the co-infected group in univariate analysis, it
was not subjected to multivariate analysis, as missing
values were > 5 %.
Comorbidities and pregnancies were not associated
with co-infection, both in overall and sub-group analysis.
Likewise, no significant association with co-infection
was elicited when each comorbidity (Table 1) was ana-
lyzed separately. Co-infection was not related to gender,
ethnicity, age and secondary DENV infections. Similarly,
there was no significant difference in the frequency of
haemorrhagic manifestations and raised haematocrit be-
tween the two groups.
The impact of DENV co-infection on disease severity
The comparison of disease severity between patients
with mono-infection and co-infection is shown in
Table 4. Majority (78 %) of patients presented with at
least one warning sign. Amongst the spectrum of warn-
ing signs, abdominal pain/tenderness (45.4 %) and per-
sistent vomiting (43.5 %) were the two most common. In
total, 17 patients (6.5 %) presented with severe dengue
manifestations: these were fluid accumulation with re-
spiratory distress (n = 7), shock (n = 4), severe bleeding
(n = 2), and severe organ impairment (n = 9). The or-
gans involved were liver (n = 4), central nervous system
(n = 4) and renal (n = 1). The DENV serotypes associ-
ated with severe dengue were: DENV-1 (n = 9), DENV-2
(n = 1), DENV-3 (n = 1) in mono-infected patients and
DENV-1/DENV-2 (n = 5) and DENV-1/DENV-3 (n = 1)
amongst those with co-infection. There was one fatality
recorded, involving a 28-year-old lady at day 46 post-
partum. She was transferred from another district hos-
pital and presented late in illness when she was already
in shock. She had secondary dengue infection and was
infected with DENV-1.
In univariate analysis (Table 4), the presence of at least
one warning sign was significantly higher amongst the
co-infected group (OR: 2.89; 95 % C1: 0.99-8.50).
Amongst the warning signs, co-infected patients were 12
times at increased risk of developing pleural effusion
(OR: 12.22; 95 % C1: 2.16-69.19). A higher proportion of
co-infected (15 %) patients had at least one severe den-
gue manifestation compared to mono-infected (5 %)
patients (OR: 3.39; 95 % C1: 1.174-9.76). Except for se-
vere bleeding, all the other entities of severe dengue
appeared at higher frequency in the co-infected group.
However, the difference was statistically significant only
for fluid accumulation with respiratory distress (OR:
8.11; 95 % C1: 1.74-37.76). Compared to the mono-
infected group, DENV-1 co-infected patients had a
significantly higher numbers of pleural effusion (OR: 9.6;
95 % C1: 1.69-54.48), severe dengue manifestations (OR:
3.25; 95 % C1: 1.08-9.76) and fluid accumulation with
respiratory distress (OR: 6.36; 95 % C1: 1.36-29.70).
Warning signs, pleural effusion and fluid accumulation
with respiratory distress were also significantly higher in
the DENV-2 co-infected group.
Multivariate analysis revealed that pleural effusion
(OR: 12.227; 95 % CI: 1.998 -74.817) and the presence of
warning signs (OR: 3.143; 95 % CI: 1.047-9.429) were
positively associated with co-infections. Subgroup ana-
lysis comparing DENV-2 mono and co-infections, re-
vealed similar characteristics as above. Subgroup analysis
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Table 2 Clinical variables at time of hospital admission: comparison between DENV co-infections and mono-infections
Characteristic All patients
(n = 262)
(%)
All mono-
infections
(n = 222) (%)
All co-infectionsa
(n = 40) (%)
OR (95 % CI) DENV-1
mono-infections
(n = 170) (%)
DENV-1
co-infectionsb
(n = 39) (%)
OR (95 % CI) DENV-2
mono-infections
(n = 44) (%)
DENV-2
co-infectionsc
(n = 35) (%)
OR (95 % CI)
Secondary 82 (31.3) 70 (31.5) 12 (30) 0.931 (0.45-1.94) 59 (34.7) 12 (30.8) 0.84 (0.4-1.8) 10 (22.7) 8 (22.9) 1.01 (0.35-2.9)
Pediatric 38 (14.5) 30 (13.5) 8(20) 1.6 (0.67-3.80) 23 (13.5) 8 (20.5) 1.65 (0.68-4.03) 6 (13.6) 7 (20) 1.58 (0.48-5.23)
Age > 55 years 18 (6.9) 14 (6.3) 4 (10) 1.65 (0.51-5.30) 12 (7.1) 4 (10.3) 1.51 (0.46-4.94) 1 (2.3) 3 (8.6) 4.03 (0.40-40.57)
Male 146 (55.7) 123 (55.4) 23 (57.5) 1.09 (0.55-2.15) 89 (52.4) 22 (56.4) 1.18 (0.58-2.37) 29 (65.9) 21 (60.0) 0.78 (0.31-1.95)
Pregnancy 14 (5.3) 12 (5.4) 2 (5) 0.92 (0.2-4.28) 9 (5.3) 2 (5.1) 0.97 (0.20-4.66) 2 (4.5) 2 (5.7) 1.27 (0.17-9.52)
Comorbidity 52 (19.8) 45 (20.3) 7 (17.5) 0.83 (0.35-2.01) 38 (22.4) 6 (15.4) 0.63 (0.25-1.62) 7 (15.9) 6 (17.1) 1.09 (0.33-3.61)
Fever 260 (99.2) 220 (99.1) 40 (100) 1.18 (1.12-1.25) 169 (99.4) 39 (100) 1.23 (1.15-1.31) 43 (97.7) 35 (100) 1.81 (1.49-2.22)
Chills and rigors 117 (44.7) 101 (45.5) 16 (40) 0.80 (0.40-1.59) 78 (45.9) 15 (38.5) 0.74 (0.36-1.50) 18 (40.9) 15 (42.9) 1.08 (0.44-2.66)
Headache 125 (47.7) 102 (45.9) 23 (57.5) 1.59 (0.81-3.14) 78 (45.9) 22 (56.4) 1.53 (0.76-3.08) 20 (45.5) 20 (57.1) 1.6 (0.65-3.91)
Cough 30 (11.5) 28 (12.6) 2 (5) 0.37 (0.08-1.60) 20 (11.8) 2 (5.1) 0.41 (0.09-1.81) 8 (18.2) 2 (5.7) 0.27 (0.05-1.38)
Nausea 72 (27.5) 59 (26.6) 13 (32.5) 1.33 (0.64-2.75) 41 (24.1) 13 (33.3) 1.57 (0.74-3.34) 15 (34.1) 10 (28.6) 0.77 (0.30-2.03)
Vomit 164 (62.6) 141 (63.5) 23 (57.5) 0.78 (0.39-1.54) 111 (65.3) 22 (56.4) 0.69 (0.34-1.40) 26 (59.1) 20 (57.1) 0.92 (0.38-2.2)
Anorexia 101 (38.7) 83 (37.4) 18 (45) 1.37 (0.69-2.70) 61 (35.9) 18 (46.2) 1.53 (0.76-3.09) 21 (47.7) 16 (45.7) 0.92 (0.38-2.25)
Abdominal pain 103 (39.3) 91 (41.0) 12 (30) 0.62 (0.30-1.28) 73 (42.9) 12 (30.8) 0.59 (0.28-1.24) 16 (36.4) 9 (25.7) 0.61 (0.23-1.61)
Diarrhoea 120 (45.8) 109 (49.1) 11 (27.5) 0.39 (0.19-0.83)* 82 (48.2) 10 (25.9) 0.37 (0.17-0.81)* 23 (52.3) 9 (25.7) 0.32 (0.12-0.83)*
Myalgia 156 (59.5) 134 (60.4) 22 (55) 0.80 (0.41-1.58) 95 (55.9) 21 (53.8) 0.92 (0.46-1.85) 34 (77.3) 19 (54.3) 0.35 (0.13-0.92)*
Arthralgia 149 (56.9) 128 (57.7) 21 (52.5) 0.81 (0.41-1.60) 90 (52.9) 20 (51.3) 0.94 (0.47-1.88) 35 (79.5) 20 (57.1) 0.34 (0.13-0.93)*
Rash 39 (14.9) 35 (15.8) 4 (10) 0.59 (0.20-1.77) 23 (13.5) 4 (10.3) 0.73 (0.24-2.25) 11 (25) 4 (11.4) 0.39 (0.11-1.34)
Neurological 20 (7.6) 17(7.7) 3 (7.5) 0.98 (0.27-3.50) 14 (8.2) 3 (7.7) 0.93 (0.25-3.40) 2 (4.5) 2 (5.7) 1.27 (0.17-9.52)
Haemorrhagic
symptoms
45 (17.2) 40(18.0) 5 (12.5) 0.65 (0.24-1.76) 34 (20) 5 (12.8) 0.59 (0.21-1.62) 2 (4.5) 4 (11.4) 2.71 (0.47-15.75)
Documented fever 189 (72.1) 159(71.6) 30 (75) 1.19 (0.55-2.58) 120 (70.6) 29 (74.4) 1.21 (0.55-2.67) 31 (70.5) 25 (71.4) 1.05 (0.39-2.79)
Tachypnoea 32 (12.3) 28(12.6) 4 (10) 0.77 (0.26-2.33) 20 (11.8) 4 (10.3) 0.86 (0.28-2.67) 8 (18.2) 4 (11.4) 0.58 (0.16-2.12)
Tachycardia 64 (24.4) 53(23.9) 11 (27.5) 1.21 (0.57-2.59) 47 (27.6) 11 (28.2) 1.03 (0.47-2.23) 6 (13.6) 10 (28.6) 2.53 (0.82-7.85)
Hypotension 22 (8.4) 20(9) 2 (5) 0.53 (0.12-2.37) 17 (10) 2 (5.1) 0.49 (0.11-2.20) 3 (6.8) 1 (2.9) 0.40 (0.04-4.04)
Bold* type represents significance at p < 0.05
aDENV-1/DENV-2 (n = 34), DENV-1/DENV-3 (n = 5), DENV-2/DENV-3 (n = 1); bDENV-1/DENV-2 (n = 34), DENV-1/DENV-3 (n = 5); cDENV-2/DENV-1 (n = 34), DENV-2/DENV-3 (n = 1)
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Table 3 Laboratory variables at time of hospital admission: comparison between DENV co-infections and mono-infections
Characteristic All patients
(n = 262)
(%)
All mono-infections
(n = 222) (%)
All co-infectionsa
(n = 40) (%)
OR (95 % CI) DENV-1
mono-infections
(n = 170) (%)
DENV-1
co-infectionsb
(n = 39) (%)
OR (95 % CI) DENV-2
mono-infections
(n = 44) (%)
DENV-2
co-infectionsc
(n = 35) (%)
OR (95 % CI)
Leukopenia 175 (66.8) 149 (67.1) 26 (65) 0.91 (0.45-1.85) 121(71.2) 25 (64.1) 0.72 (0.35-1.51) 21 (47.7) 21 (60) 1.64 (0.67-4.04)
Platelet < 50,000/
mm3
39 (14.9) 30 (13.5) 9 (22.5) 1.86 (0.81-4.29) 27(15.9) 9 (23.1) 1.59 (0.68-3.72) 1 (2.3) 7 (20) 10.75 (1.25-92.16)*
Raised
haematocrit
142 (54.2) 117 (52.7) 25 (62.5) 1.50 (0.75-2.99) 88(51.8) 23 (59) 1.34 (0.66-2.71) 23 (52.3) 23 (65.7) 1.75 (0.7-4.37)
Raised uread 11 (4.6) 9 (4.5) 2 ( 5.4) 1.22( 0.25-5.88) 7(4.5) 2 (5.6) 1.25 (0.25-6.30) 2 (5.4) 2 (6.2) 1.17 (0.16-8.79)
Low sodium 9 (3.7) 7 (3.4) 2 (5.3) 1.58 (0.32-7.91) 6(3.8) 2 (5.4) 1.45 (0.28-7.48) 1 (2.5) 2 (6.1) 2.52 (0.22-29.05)
Low potassium 168 (68.9) 145 (70.4) 23 (60.5) 0.65 (0.32-1.32) 108(68.4) 22 (59.5) 0.68 (0.33-1.42) 31 (77.5) 21 (63.6) 0.51 (0.18-1.42)
Raised creatininee 32 (13.5) 22 (11.1) 10 (26.3) 2.87 (1.23-6.70)* 18(11.7) 10 (27) 2.80 (1.17-6.72)* 4 (10.8) 9 (27.3) 3.09 (0.85-11.24)
Raised bilirubin 12 (4.8) 10 (4.7) 2 (5.3) 1.12 (0.24-5.31) 9(5.6) 2 (5.4) 0.97 (0.2-4.67) 1 (2.4) 2 (6.1) 2.65 (0.23-30.51)
Low albumin 7 (2.8) 6 (2.8) 1 (2.6) 0.94 (0.11-8.01) 4(2.4) 1 (2.7) 1.11 (0.12-10.24) 2 (4.8) 1 (3) 0.63 (0.05-7.21)
Raised ASTf 133 (78.2) 114 (78.6) 19 (76) 0.86 (0.32-2.34) 90(81.1) 19 (79.2) 0.89 (0.30-2.65) 19 (65.5) 17 (77.3) 1.79 (0.51-6.29)
Raised ALT 153 (61) 133 (62.4) 20 (52.6) 0.67 (0.33-1.34) 108(65.9) 20 (54.1) 0.61 (0.30-1.26) 20 (47.6) 19 (57.6) 1.49 (0.60-3.74)
Bold* type represents significance at p < 0.05
aDENV-1/DENV-2 (n = 34), DENV-1/DENV-3 (n = 5), DENV-2/DENV-3 (n = 1); bDENV-1/DENV-2 (n = 34), DENV-1/DENV-3 (n = 5); cDENV-2/DENV-1 (n = 34), DENV-2/DENV-3 (n = 1)
dData available for 238 cases, eData available for 237 cases, fData available for 170 cases
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Table 4 Clinical characteristics based on disease severitya: Comparison between DENV co-infections and mono-infections
Characteristic All patients
(n = 262)
(%)
All mono-
infections
(n = 222)
(%)
All co-infectionsb
(n = 40) (%)
OR (95 % CI) DENV-1
mono-infections
(n = 170) (%)
DENV-1
co-infectionsc
(n = 39) (%)
OR (95 % CI) DENV-2
mono-infections
(n = 44) (%)
DENV-2
co-infectionsd
(n = 35) (%)
OR (95 % CI)
Any warning signs 204 (77.9) 168 (75.7) 36 (90) 2.89 (0.99-8.50)* 134 (78.8) 35 (89.7) 2.35 (0.78-7.05) 29 (65.9) 32 (91.4) 5.52 (1.45-21.02)*
Persistent vomiting 114 (43.5) 99 (44.6) 15 (37.5) 0.75 (0.37-1.49) 82 (48.2) 15 (38.5) 0.67 (0.33-1.37) 14 (31.8) 13 (37.1) 1.27 (0.50-3.22)
Abdominal pain/
tenderness
119 (45.4) 100 (45) 19 (47.5) 1.10 (0.56-2.17) 81 (47.6) 19 (48.7) 1.04 (0.52-2.09) 17 (38.6) 16 (45.7) 1.34 (0.54-3.29)
Mucosal bleeding 64 (24.4) 52 (23.4) 12 (30) 1.40 (0.67-2.95) 38 (22.4) 12 (30.8) 1.54 (0.72-3.33) 10 (22.7) 12 (34.3) 1.77 (0.66-4.78)
Tender hepatomegaly 9 (3.4) 7 (3.2) 2 (5) 1.62 (0.32-8.08) 3 (1.8) 2 (5.1) 3.01 (0.49-18.65) 4(9.1) 2 (5.7) 0.61 (0.10-3.52)
Pleural effusion 6 (2.3) 2 (0.9) 4 (10) 12.22 (2.16-69.19)* 2 (1.2) 4 (10.3) 9.6 (1.69-54.48)* 0 4 (11.4) OR Undefined*
(p = 0.035)
Increasing haematocrit
with decreasing platelets
64 (24.4) 52 (23.4) 12 (30) 1.40 (0.67-2.95) 41 (24.1) 11 (28.2) 1.24 (0.57-2.70) 10 (22.7) 11 (31.4) 1.56 (0.57-4.25)
Any severe dengue
manifestations
17 (6.5) 11 (5) 6 (15) 3.39 (1.174-9.76)* 9 (5.3) 6 (15.4) 3.25 (1.08-9.76)* 1 (2.3) 5 (14.3) 7.17 (0.80-64.49)
Shock 4 (1.5) 3 (1.4) 1 (2.5) 1.87 (0.19-18.46) 2 (1.2) 1 (2.6) 2.21 (0.20-25.01) 1 (2.3) 0 OR Undefined
Fluid accumulation with
respiratory distress
7 (2.7) 3 (1.4) 4 (10) 8.11 (1.74-37.76)* 3 (1.8) 4 (10.3) 6.36 (1.36-29.70)* 0 4 (11.4) OR Undefined*
(p = 0.035)
Severe bleeding 2 (0.8) 2 (0.9) 0 OR Undefined 1 (0.6) 0 OR Undefined 0 0 NA
Severe organ
involvement
9 (3.4) 7 (3.2) 2 (5.0) 1.62 (0.32-8.08) 7 (4.1) 2 (5.1) 1.26 (0.25-6.31) 0 2 (5.7) OR Undefined
ICU 4 (1.5) 4 (1.8) 0 OR Undefined 4 (2.4) 0 OR Undefined 0 0 NA
Oxygen supplementation 7 (2.7) 5 (2.3) 2 (5) 2.28 (0.43-12.20) 5 (2.9) 2 (5.1) 1.78 (0.33-9.55) 0 2 (5.7) OR Undefined
Mechanical ventilation 4 (1.5) 4 (1.8) 0 OR Undefined 4 (2.4) 0 OR Undefined 0 0 NA
Hospitalization > 3 days 96 (36.6) 84 (37.8) 12 (30) 0.70 (0.34-1.46) 60 (35.3) 12 (30.8) 0.82 (0.39-1.72) 21 (47.7) 11 (31.4) 0.50 (0.20-1.27)
Bold* type represents significance at p < 0.05. aDisease severity is based on WHO (2009) classification plus additional clinical criteria
bDENV-1/DENV-2 (n = 34), DENV-1/DENV-3 (n = 5), DENV-2/DENV-3 (n = 1); cDENV-1/DENV-2 (n = 34), DENV-1/DENV-3 (n = 5); dDENV-2/DENV-1 (n = 34), DENV-2/DENV-3 (n = 1),
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comparing DENV-1 mono and co-infected patients, re-
vealed that pleural effusion (OR: 11.824; 95 % CI: 1.936-
72.203) was positively associated with co-infections. The
associations in the multivariate analysis were maintained
when adjusted for comorbidity and patients with sec-
ondary dengue infections.
We found no statistical differences between the two
groups and its sub-groups in other manifestations of
disease severity, such as hypotension, shock, admission
to an intensive care unit, the need for mechanical venti-
lation or supplemental oxygen and hospitalization dur-
ation of > 3 days. The median (IQR) length of hospital
stay was 3 (1–16) days for the mono-infected and 3 (1–
18) days for the co-infected groups.
Discussion
The co-circulation of multiple DENV serotypes within a
similar geographical area provides a suitable niche for
the occurrence of co-infections, a phenomenon best ob-
served during epidemics [8, 10, 11, 14–17]. The first case
of co-infection with 2 dengue virus serotypes (DENV-1
and DENV-4) was reported in Puerto Rico in 1982 [29].
Since then, various reports have emerged from various
countries describing the occurrence of co-infections. Co-
infection rates vary widely in different countries and dif-
ferent regions within the same country. In the present
study, the overall co-infection rate was 15 %. These rates
were comparable to those in New Delhi [10, 11], Ceylon
[30] and Vietnam [12], whereas other regions such as
Indo-China [9], Brazil [15], Kerala [16] and Karnataka
[17] have reported higher rates. Nevertheless, very few
of these studies have specifically explored the clinical
impact of co-infection as the actual number of co-
infected cases in these studies have been rather small.
To the best of our knowledge, this study provides the
most in-depth insight of the association between co-
infection and the various clinical and laboratory parame-
ters and also has the largest pool of co-infected cases.
In the present study, there was an overwhelming pre-
dominance of DENV-1, followed by DENV-2 and
DENV-3, with only one patient infected with DENV-4.
Correspondingly, the common co-infections involved
the most common DENV serotypes, as evidenced by an
overwhelming co-infections caused by DENV-1/DENV-2
(85 %) followed by DENV-1/DENV-3 (12.5 %). The re-
sults of multiplex PCR from both the original serum and
first passage of the supernatant of C6/36 serum infected
cells demonstrated consistency in terms of determining
the serotypes of the DENV.
Phylogenetic analysis indicated that the DENV strains
were not clonal and showed heterogeneity amongst
them. The close relatedness of the DENV isolates as
revealed by monophyletic clustering indicated local
dengue outbreaks. In addition, this study significantly
expanded the number of Malaysian DENV-1 whole ge-
nomes by 5-fold and to our knowledge, is the first to
report the complete DENV-2 genomes from Malaysia.
It may be possible to acquire co-infection from a sin-
gle mosquito bite in endemic areas where more than
one serotypes are circulating, as the presence of two
DENV serotypes in one mosquito has been shown [31].
Co-infection may also be possible if the patient is bitten
by two different mosquitos within a short period. The
chances of dual dengue infections of humans are further
enhanced because of the feeding behaviour of Aedes
aegypti [14]. Female Ae. aegypti feeds numerous times
on human host during each gonotrophic cycle, increas-
ing the opportunities of spreading Ae. aegypti borne-
disease [32]. Furthermore, the time spent probing is
lengthier in infected compared to uninfected Ae. Aegypti
mosquitoes. Longer feeding periods encourages more
host defensive behaviours against the blood-seeking
mosquitoes, increasing the probability that an infected
mosquito will probe on additional hosts [33]. This feed-
ing behaviour facilitates dual infections in mosquitoes
with subsequent transmission of multiple DENV to sin-
gle human host [14].
Apart from the typical dengue-related symptoms, it
was interesting to note that diarrhoea was the presenting
symptom in almost half of the patients. Significantly
higher frequency of diarrhoea was noted amongst the
mono-infected compared with co-infected patients.
Other gastrointestinal symptoms also appeared higher in
the mono-infected group, although not statistically sig-
nificant. Cytokines and interleukins (ILs) play a major
role in the pathogenesis of dengue fever, with a possible
role of IL-8 in the pathogenesis of dengue-associated
diarrhoea [34]. Co-infections may result in synergistic or
antagonistic interactions which may alter disease patho-
genesis, thus altering the clinical presentation of disease.
Another difference observed on subgroup analysis was
that DENV-2 mono-infected patients were more likely
to present with myalgia and arthralgia compared to co-
infected patients. Conversely, in another Brazilian study,
arthralgia was more common amongst the co-infected
patients [8]. However, apart from gastrointestinal and
musculoskeletal symptoms, we found no other individual
symptoms or group of symptoms that distinguished
DENV mono and co-infections.
The frequency of patients with severe thrombocytopenia
on admission and lower nadir platelet counts was signifi-
cantly higher amongst the DENV-2 co-infected compared
to mono-infected patients. Likewise, the association be-
tween low platelets and DENV co-infection was also noted
in another study [8]. While some studies revealed a higher
frequency of haemorrhagic manifestations amongst DENV
co-infected patients [8, 10, 17]; concurring with other stud-
ies [12, 14] we found no such association. This supports
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previous findings that the degree of thrombocytopenia does
not necessarily correlate with haemorrhage, and other trig-
gers such as liver injury, vasculopathy, activation of coagu-
lation and fibrinolytic system, release of pro-inflammatory
cytokines and platelet dysfunction may contribute towards
dengue associated bleeding diatheses [35].
Controversy still exists as to whether the presence of
co-infection increases disease severity. In the present
research, the presence of warning signs (90 %) and other
severe disease manifestations (15 %) were significantly
higher amongst patients with DENV co-infection, con-
curring with a recent study in Brazil which revealed that
61 % of the co-infected patients had either severe den-
gue or dengue with warning signs [8]. Although pleural
effusion was significantly more common amongst the
co-infected patients, there was no corresponding in-
crease in other parameters of plasma leakage such as
hypoalbuminaemia or raised haematocrit. This could
partially be explained by the fact that we analyzed these
parameters upon admission, which could possibly alter
during the course of disease. Binh PT et al. reported no
increase in plasma leakage amongst DENV co-infected
patients [12]. Neither was there an increased occurrence
of gallbladder thickening which reflects tissue oedema
resulting from plasma leakage [12].
The mechanisms of disease virulence and the resulting
clinical manifestations in DENV co-infections remains
largely unclear. Heterogeneity in patient characteristics,
differences in patient population i.e. outpatient verses
hospitalized patients, differences in DENV serotypes and
variances in the parameters assessed may explain the dif-
ferences found. Furthermore, the studies reported so far
have involved relatively small numbers of co-infections,
making statistical inferences difficult. The possible clin-
ico- pathological effects of DENV co-infections resulting
from direct interactions of viral genes or indirect inter-
actions resulting in alterations in the host-environment
or immunological changes [36], need further explor-
ation. The presence of DENV co-infection is likely to
increase DENV viremia levels [8]. Higher viremia early
in the course of infection has been linked to increased
disease severity and higher frequency of pleural effusion
[35, 37]. Another worrying consequence of co-infections
is the possible occurrence of recombination events [38],
which may result in alteration of DENV virulence.
Strengths and limitations
The strength of this study is that it involved a large
number of co-infected patients, allowing more reliable
data interpretation. Moreover, since blood samples were
collected during the acute phase of disease, the serum
samples were NS1 antigen and RT-PCR positive, which
permitted serotyping and viral isolation.
However, there are several limitations to this current
study. All retrospective studies depend on the obtain-
ability, accuracy and completeness of medical data.
Therefore, the influence of certain clinical findings such
as petechial rash and Hess’s test were difficult to deter-
mine as these tests/findings may not have been per-
formed or recorded in medical charts. Moreover, this
study had a relatively small number of patients with
pleural effusion which may result in a low statistical
power to detect true association. Chest x-rays were per-
formed at the discretion of the attending clinicians,
according to clinical findings. However, chest x-rays can
only detect significant pleural effusions. The use of serial
chest ultrasound can improve detection of small pleural
effusions [39], although this may not be practical be-
cause of budgetary constraints and service restraints.
However, despite this, all patients were managed with a
standardized dengue clinical care management algorithm
and laboratory and clinical parameters essential for pa-
tient monitoring were carefully recorded in the medical
charts, which helped improve reliability of data collected.
While a prospective study would be more reliable and
accurate, the practicality of such a study is questionable
because of the low numbers of co-infections in most re-
ports. Finally, our study was conducted in a tertiary refer-
ral hospital and involved only hospitalized patients. Thus,
these findings may not be generalized to patients with less
severe manifestations, not necessitating hospitalization.
Conclusion
In conclusion, our findings suggest that DENV co-infec-
tions are not a rare occurrence and may play a previously
unrecognized role in the pathogenesis, virulence and clin-
ical expression of disease. Patients with co-infections
seemed lop-sided towards more severe clinical manifesta-
tions as evidenced by a higher frequency of severe
thrombocytopenia, pleural effusion, elevations of creatinine
levels, and the presence of warning signs. However, haem-
orrhagic manifestations and haemoconcentration did not
appear to be higher in the co-infected group. Co-infections
may also alter clinical presentation as suggested by a lower
number of diarrhoea and arthralgia/myalgia symptoms
amongst these patients compared to the mono-infected
patients. Although our report illuminates important finding
on the impact of DENV co-infections, a prospective study
performed on a larger scale will be useful to further
strengthen these findings. Exploration of cellular immune
response and host cytokines associated with DENV co-
infections is a logical next step.
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